Navigation Links
ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
Date:1/8/2009

-a-day), 400 mg bid or 800 mg bid. Ten patients are to be enrolled at each dose level, eight receiving active drug and two receiving placebo.

In a Phase I study in healthy volunteers, ANA598 was administered as capsules at single oral doses of 400 mg, 800 mg, 1400 mg, 2000 mg (fed and fasted) and 3000 mg. In addition, a separate cohort received two 800 mg doses 12 hours apart. ANA598 was well tolerated at all doses and there were no serious adverse events or withdrawals from the study. All reported adverse events were classified as mild or moderate, with no apparent dose relationship. The pharmacokinetic profile demonstrated sustained plasma levels of ANA598 consistent with the potential for once-daily or twice-daily oral dosing.

In the preclinical program, ANA598 was well tolerated at all doses tested in 28-day GLP toxicology studies. In September 2008, Anadys initiated long-term, chronic toxicology studies of ANA598.

If ANA598 is successful in early stage development, the Company anticipates completion of the clinical, toxicology and manufacturing activities required to initiate Phase II studies of ANA598 in combination with current standard of care in mid-2009.

Webcast of Conference Call

Anadys will host a conference call today, January 8, 2009 at 8:30 a.m. Eastern Standard Time (5:30 a.m. Pacific Standard Time) to discuss the results from the first cohort of the ongoing Phase Ib clinical trial of ANA598. A live webcast of the call will be available online at www.anadyspharma.com. A telephone replay will also be available approximately one hour after completion of the call. To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 99568266. The webcast and telephone replay will be available through January 22, 2009.

Clinical Need and Mar
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
8. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
9. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
10. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
11. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... On August 31, 2015, United States District ... 123-page order in the first of the consolidated MDL ... replacement devices are defective.[1]  The Court ... Robyn Christiansen,s claims for defective design, fraudulent misrepresentation and ... Medical,s claim that the Medical Device Amendment to the ...
(Date:9/1/2015)... , Sept. 1, 2015  Amgen (NASDAQ: ... Novartis in the areas of Alzheimer,s disease and ... Alzheimer,s disease by teaming up with Novartis on ... directed at genetically predisposed individuals at risk of ... focus on the commercialization of its migraine programs ...
(Date:9/1/2015)... and Delaware , United ... (ASX: IVX; "Company" or "Invion"), is pleased to announce that ... securities to an institutional investor in the United ... proceeds of approximately A$1.001 million ("Placement") by the issue of ... of $0.014 per share. The Company has ...
Breaking Medicine Technology:Pope McGlamry: Omnibus order in Conserve Hips MDL-2329 sets stage for bellwether trial 2Pope McGlamry: Omnibus order in Conserve Hips MDL-2329 sets stage for bellwether trial 3Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 2Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 3Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 4Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 5Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 6Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 7Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 8Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 9Invion Announces Private Placement to US Institutional Investor 2Invion Announces Private Placement to US Institutional Investor 3
... Reportlinker.com announces that a new market research report is available in its catalogue: , ... Relieving Drug Market Analysis 2010-2025 , , , ... , Reports details , ... opportunities lie in this diverse market with high, growing demand worldwide? , , ...
... WESTLAKE VILLAGE, Calif. , May 4 ... provider of specialty physician consultations via telemedicine, announced today ... Organization,s 2010 Innovations in Healthcare ABBY Award.  SOC won ... category for their 24/7 teleneurology service that provides immediate ...
Cached Medicine Technology:Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 2Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 3Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 4Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 5Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 6Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 7Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 8Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 9Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 10Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 11Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 12Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 13Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 14Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 15Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 16Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 17Specialists On Call Wins 2010 Innovations in Healthcare ABBY Award 2
(Date:9/1/2015)... ... September 01, 2015 , ... The ... the treatment of androgenic alopecia in adults, announces Miami-based medical device manufacturer, Capillus, ... while also demonstrating its safety when used at home to combat hair loss. ...
(Date:9/1/2015)... ... September 01, 2015 , ... ProRehab Physical Therapy , ... partnership with Apex Physical Therapy (Apex) is official as of August ... compassionate, and empathetic care to local residents from their combined eight locations throughout ...
(Date:9/1/2015)... ... , ... From Aug. 17-21, Calvary Hospital hosted the 18th consecutive session of ... has taken place at Kingsborough Community College in Brooklyn in each of the past ... Calvary, and two junior counselors who were campers themselves just a few years ago. ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... cure and prevent different malignancies. Some options for cancer treatment are available ... to which distinctive approach is necessary for effective treatment. Several molecules have ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... creates negative pressure inside a wound to remove exudates, fluid, and infectious materials ... (comprising portable devices, stand-alone devices, disposable devices, and canisters, etc.) is projected to ...
Breaking Medicine News(10 mins):Health News:Capillus82™ Laser Therapy Cap Receives FDA Clearance for Treatment of Hair Loss 2Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 2Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 3Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 3Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3
... Tools to Help Make More ,Cents, of,Grocery Bills, WASHINGTON, ... celebrity to join the famed Milk Mustache campaign, this time,to ... many,families are economizing on groceries but one thing they should ... 8 ounce glass, on a gallon,basis, milk offers more nutrients ...
... On September 30, 2008,viewers tuning in to ... ) will find hope for stuttering. That day, ... M.A., CCC-SP,founder of Power Stuttering Center ( http://www.powerstuttering.com ... eliminated by the SpeechEasy(R),Stuttering Device., Power, a ...
... Open enrollment season,throughout corporate America is rapidly approaching, ... important decisions about their employee,benefit coverage for next ... an,increased emphasis on personal health behaviors as well ... services and programs, according to,benefit consultants at Watson ...
... offers no concrete answers , , MONDAY, Sept. 29 (HealthDay News) ... more likely to die after surgery than those who live ... study analyzed death rates among more than one million older ... cancer surgeries between 1999 and 2003. , The risk ...
... ... Study, ... released its first study: "Choosing a Health Plan:,What Should Consumers Look ... statements designed,to help create more informed consumers and improve health care ...
... Industries,Inc. (Nasdaq: HRLY ) announced today that ... a contract totaling approximately $1.3 million,from Lockheed Martin ... switch filter assemblies for the MH-60R helicopter in ... Multi-Mission Helicopter (MMH) is the U.S. Navy,s new,primary ...
Cached Medicine News:Health News:Suze Orman Joins got milk? Milk Mustache Campaign: New Ad Encourages Families To Invest in Milk's Nutritional Assets 2Health News:Suze Orman Joins got milk? Milk Mustache Campaign: New Ad Encourages Families To Invest in Milk's Nutritional Assets 3Health News:Help for Stutterers on 'The Doctors' TV Show Presented by Power Stuttering Center Founder Mark Power 2Health News:Watson Wyatt Identifies Trends for Benefits Open Enrollment Season 2Health News:Watson Wyatt Identifies Trends for Benefits Open Enrollment Season 3Health News:Seniors in Poor Areas More Likely to Die After Surgery 2Health News:Access to Physicians Is Consumers' Highest Priority When Choosing a Health Plan, According to New Study 2Health News:Access to Physicians Is Consumers' Highest Priority When Choosing a Health Plan, According to New Study 3Health News:Herley New England Receives Additional $1.3 Million Contract Award from Lockheed Martin for the Multi-Mission Helicopter 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: